This listing of the claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

(currently amended) A compound of the following formula:

**(I)** 

or the pharmaceutically acceptable salts thereof, wherein

one of  $Y^1$ ,  $Y^2$ ,  $Y^3$  and  $Y^4$  is N and the others are independently selected from N, CH or and C(L);

R<sup>1</sup> is H, C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-8</sub> alkoxy, halosubstituted C<sub>1-8</sub> alkoxy, C<sub>1-8</sub> alkyl-S(O)m-, Q<sup>1</sup>-, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, amino, mono- or di-(C<sub>1-8</sub> alkyl)amino, C<sub>1-4</sub>alkyl-C(=O)-N(R<sup>3</sup>)- or C<sub>1-4</sub>alkyl-S(O)m-N(R<sup>3</sup>)-, wherein said C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl and C<sub>2-8</sub> alkynyl are optionally substituted with halo, C<sub>1-3</sub> alkyl, hydroxy, oxo, C<sub>1-4</sub> alkoxy-, C<sub>1-4</sub> alkyl-S(O)m-, C<sub>3-7</sub> cycloalkyl-, cyano, indanyl, 1,2,3,4-tetrahydronaphtyl, 1,2-dihydronaphtyl, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, Q<sup>1</sup>-, Q<sup>1</sup>-C(=O)-, Q<sup>1</sup>-O-, Q<sup>1</sup>-S(O)m-, Q<sup>1</sup>-C<sub>1-4</sub>alkyl-O-, Q<sup>1</sup>-C<sub>1-4</sub>alkyl-S(O)m-, Q<sup>1</sup>-C<sub>1-4</sub>alkyl-C(O)-N(R<sup>3</sup>)-, Q<sup>1</sup>-C<sub>1-4</sub>alkyl-N(R<sup>3</sup>)- or C<sub>1-4</sub>alkyl-C(O)-N(R<sup>3</sup>)-;

Q<sup>1</sup> is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, and is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, amino, mono- or di-(C<sub>1-4</sub>alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-

 $C_{1-4}$ alkyl,  $C_{1-4}$  alkylsulfonyl, aminosulfonyl,  $C_{1-4}$ alkylC(=0)-, HO(O=)C-,  $C_{1-4}$ alkyl-O(O=)C-,  $R^3N(R^4)C(=0)$ -,  $C_{1-4}$  alkylsulfonylamino,  $C_{3-7}$  cycloalkyl,  $R^3C(=0)N(R^4)$ - or  $NH_2(HN=)C-;$ 

- 3 -

A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, wherein said 5-6 membered monocyclic aromatic ring is optionally substituted with up to 3 substituents selected from halo, C1-4 alkyl, halo-substituted C1-4 alkyl, hydroxy, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, nitro, amino, mono- or di-(C $_{1}$ 4 alkyl)amino, cyano, HO-C $_{1}$ 4 alkyl, C $_{1}$ 4 alkoxy-C $_{1}$ 4 alkyl, C $_{1}$ 4 alkyl, C $_{1}$ 5 alkyl, C $_{1}$ 5 alkyl, C $_{1}$ 5 alkyl, C $_{1}$ 6 alkyl, C $_{1}$ 7 alkyl, C $_{1}$ 8 alkyl, C $_{1}$ 8 alkyl, C $_{1}$ 9 alkyl, alkylsulfonyl, aminosulfonyl, acetyl, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, HO(O=)C-, C<sub>1-4</sub>alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, R<sup>3</sup>C(=O)N(R<sup>4</sup>)- and NH<sub>2</sub>(HN=)C-; B is halo-substituted C<sub>1-6</sub> alkylene, C<sub>3-7</sub> cycloalkylene, C<sub>2-6</sub> alkenylene, C<sub>2-6</sub> alkynylene, -O-C1-5 alkylene, C1-2 alkylene-O-C1-2 alkylene or C1-6 alkylene optionally substituted with an oxo group or C<sub>1-3</sub> alkyl;

W is NH, N-C<sub>1-4</sub> alkyl, O, S, N-OR<sup>5</sup> or a covalent bond;

 $\mathbb{R}^2$  is H,  $\mathbb{C}_{1-4}$  alkyl, OH or  $\mathbb{C}_{1-4}$  alkoxy;

Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkenyl, C<sub>1-4</sub> alkynyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, amino, mono- or di-(C1-4 alkyl)amino, cyano, HO-C1-4 alkyl, C1-4 alkoxy-C1-4alkyl,  $C_{1-4}$  alkylsulfonyl, aminosulfonyl,  $C_{1-4}$ alkylC(=0)-,  $R^3C(=0)N(R^4)$ -, HO(0=)C-,  $C_{1-4}$ alkylsulfonyl, aminosulfonyl,  $C_{1-4}$ alkylC(=0)-,  $C_{1-4}$ alkylsulfonyl, aminosulfonyl,  $C_{1-4}$ alkylC(=0)-,  $C_{1-4}$ alkyl $C_{$ 4alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, NH<sub>2</sub>(HN=)C-, Q<sup>2</sup>-S(O)m-, Q<sup>2</sup>-O-,  $O^2$ -N( $\mathbb{R}^3$ )- or  $\mathbb{Q}^2$ -; L is halo,  $C_{1-4}$  alkyl, halo-substituted  $C_{1-4}$  alkyl, hydroxy,  $C_{1-4}$  alkoxy, halo-substituted  $C_{1-4}$ 

4 alkoxy, C<sub>1-4</sub> alkylthio, nitro, amino, mono- or di-(C<sub>1-4</sub> alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl,  $C_{1-4}$  alkoxy- $C_{1-4}$ alkyl,  $C_{1-4}$  alkylsulfonyl, aminosulfonyl,  $C_{1-4}$ alkylC(=O)-, HO(O=)C-,  $C_{1-4}$ alkyl 4alkyl-O(O=)C-,  $C_{1-4}$  alkylsulfonylamino,  $C_{3-7}$  cycloalkyl,  $R^3C(=0)N(R^4)$ -,  $NH_2(HN=)C$ -,

 ${\rm R}^3{\rm N}({\rm R}^4){\rm C}(={\rm O})\text{-, }{\rm R}^3{\rm N}({\rm R}^4){\rm S}({\rm O}){\rm m}\text{-, }{\rm Q}^2\text{--}{\rm Q}^2\text{--}{\rm C}(={\rm O})\text{-, }{\rm Q}^2\text{--}{\rm O}\text{-, }{\rm Q}^2\text{--}{\rm C}_1\text{--}4{\rm alkyl}\text{--}{\rm O}\text{-, or two}$ adjacent L groups are optionally joined together to form an alkylene chain having 3 or 4 members in which one or two (non-adjacent) carbon atoms are optionally replaced by oxygen

m is 0, 1 or 2;

atoms;

R<sup>3</sup> and R<sup>4</sup> are independently selected from H and C<sub>1-4</sub> alkyl;

PATENT PFIZER ANN ARBOR MI

 $R^5$  is H,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkyl-(O=)C- or  $C_{1-4}$  alkyl-O-(O=)C-; and

O<sup>2</sup> is a 5-12 membered monocyclic or bicyclic aromatic ring, or a 5-12 membered tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted  $C_{1-4}$  alkyl,  $C_{1-4}$   $C_{2-4}$  alkenyl,  $C_{1-4}$  alkynyl, hydroxy,  $C_{1-4}$ alkoxy, halo-substituted C11.4 alkoxy C11.4 alkoxy, C1.4 alkylthio, nitro, amino, mono- or  $\label{eq:continuous} \begin{array}{lll} \text{di-}(C_{1-4} \text{ alkyl}) \text{amino, cyano, HO-} C_{1-4} \text{ alkyl, } C_{1-4} \text{ alkoxy-} C_{1-4} \text{ alkyl, } C_{1-4} \text{ alkylsulfonyl, } \\ \end{array}$ aminosulfonyl, C<sub>1-4</sub>alkyl- (O=)C-, R<sup>3</sup>(R<sup>4</sup>)C(=O)N-, HO(O=)C-, C<sub>1-4</sub> alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, C<sub>1-4</sub> alkyl-C(=O)NH- or NH<sub>2</sub>(HN=)C-.

2. (currently amended) A compound according to Claim 1, wherein one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup>, and Y<sup>4</sup> is N and the others are independently selected from N, CH and C(L);R1 is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, C1-8 alkoxy, halosubstituted C<sub>1-8</sub> alkoxy, C<sub>1-8</sub> alkyl-S(O)m-, Q<sup>1</sup>-, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, amino, mono- or di-(C1-8 alkyl)amino, C1-4alkyl-C(=0)-N(R3)- or C1-4alkyl-S(O)m-N(R<sup>3</sup>)-, wherein said C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl and C<sub>2-8</sub> alkynyl are optionally substituted with halo, C<sub>1-3</sub> alkyl, hydroxy, oxo, C<sub>1-4</sub> alkoxy-, C<sub>1-4</sub> alkyl-S(O)m-, C<sub>3-7</sub> cycloalkyl-, cyano, indanyl, 1,2,3,4-tetrahydronaphtyl, 1,2-dihydronaphtyl, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, Q1-, Q1-C(=O)-, Q1-O-, Q1-S(O)m-, Q1-C<sub>1-4</sub> alkyl-O-, Q<sup>1</sup>-C<sub>1-4</sub> alkyl-S(O)m-, Q<sup>1</sup>-C<sub>1-4</sub>alkyl-C(=O)-N(R<sup>3</sup>)-, or C<sub>1-4</sub>alkyl-C(=O)-N(R<sup>3</sup>)-;

From-

Q1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, and is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, amino, mono- or di-(C<sub>1-4</sub> alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkylC(=O)-, HO(O=)C-, C<sub>1-4</sub> alkyl-O(O)C-, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, R<sup>3</sup>C(=O)N(R<sup>4</sup>)- or NH<sub>2</sub>(HN=)C-;

A is a 5-6 membered monocyclic aromatic ring optionally containing up to 2 heteroatoms selected from O, N, and S, wherein said 5-6 membered monocyclic aromatic ring is optionally substituted with up to 2 substituents selected from halo,  $C_{1-4}$  alkyl, halo-substituted  $C_{1-4}$  alkyl, hydroxy,  $C_{1-4}$  alkoxy and halo-substituted  $C_{1-4}$  alkoxy;

B is  $C_{3-7}$  cycloalkylene or  $C_{1-6}$  alkylene optionally substituted with an oxo group or  $C_{1-3}$  alkyl;

W is NH, N-C<sub>1-4</sub> alkyl, O or N-OH;

R<sup>2</sup> is H or C<sub>1-4</sub> alkyl;

Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkenyl, hydroxy, C<sub>1-4</sub> alkoxy, nitro, amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkylC(=O)-, R<sup>3</sup>C(=O)N(R<sup>4</sup>)-, HO(O=)C-, C<sub>1-4</sub> alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>1-4</sub> alkyl-C(=O)NH-, Q<sup>2</sup>-S(O)m-, Q<sup>2</sup>-O-, Q<sup>2</sup>-N(R<sup>3</sup>)- or Q<sup>2</sup>-; L is halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, mono- or di-(C<sub>1-4</sub> alkyl)amino, halo-substituted C<sub>1-4</sub> alkoxy, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkylC(=O)-, HO(O=)C-, C<sub>1-4</sub> alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, R<sup>3</sup>C(=O)N(R<sup>4</sup>)-, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, R<sup>3</sup>N(R<sup>4</sup>)S(O)m-, Q<sup>2</sup>-, Q<sup>2</sup>-C(=O)-, Q<sup>2</sup>-O-, Q<sup>2</sup>-C<sub>1-4</sub>alkyl-O-, or two adjacent L groups are optionally joined together to form an alkylene chain having 3 or 4 members in which one or two (non-adjacent) carbon atoms are optionally replaced by oxygen atoms;

PATENT PFIZER ANN ARBOR MI

<del>-</del> 6 -

m is 0 or 2;

R3 and R4 are independently selected from H and C1\_4 alkyl; and

Q2 is a 5-12 membered monocyclic or bicyclic aromatic ring, or a 8-12 membered tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C1-4 alkyl, halo-substituted  $C_{1-4}$  alkyl,  $G_{1-4}$   $C_{2-4}$  alkenyl,  $G_{1-4}$   $C_{2-4}$  alkynyl, hydroxy,  $C_{1-4}$ alkoxy, halo-substituted  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio, mono- or di- $(C_{1-4}$  alkyl)amino, cyano,

HQ-C1 4 alkyl- C1 4 alkoxy-C1 4 alkyl- Received from < 7346222928 > at 6/20/03 12:15:39 PM [Eastern Daylight Time]

T-402 P.010/026 F-385

m is 0 or 2;

R3 and R4 are independently selected from H and C1-4 alkyl; and

Q2 is a 5-12 membered monocyclic or bicyclic aromatic ring, or a 8-12 membered tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C1-4 alkyl, halo-substituted C<sub>1-4</sub> alkyl, G<sub>1-4</sub> C<sub>2-4</sub> alkenyl, G<sub>1-4</sub> C<sub>2-4</sub> alkynyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, mono- or di-(C1-4 alkyl)amino, cyano,  $HO-C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy- $C_{1-4}$  alkyl,  $C_{1-4}$  alkylsulfonyl, aminosulfonyl,  $C_{1-4}$  alkyl-(O=)C-,  $R^3(R^4)C(=O)N-$ , HO(O=)C-,  $C_{1-4}$  alkyl-O(O=)C-,  $C_{1-4}$  alkylsulfonylamino,  $C_{3-7}$ cycloalkyl or C<sub>1-4</sub> alkyl-C(=O)NH-.

3. (currently amended) A compound according to Claim 2, wherein

one of Y1, Y2, Y3, and Y4 is N and the others are independently selected from N, CH and C(L);  $\mathbb{R}^1$  is H,  $\mathbb{C}_{1-8}$  alkyl,  $\mathbb{C}_{2-8}$  alkenyl,  $\mathbb{C}_{2-8}$  alkynyl,  $\mathbb{C}_{3-7}$  cycloalkyl,  $\mathbb{Q}^1$ -, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, amino, mono- or di-(C1-8 alkyl)amino, wherein said C1-8 alkyl is optionally substituted with halo,  $C^{1-3}$ -alkyl  $C_{1-3}$  alkyl, hydroxy, oxo,  $C_{1-4}$  alkoxy-,  $C_{1-4}$ alkyl-S(O)m-, C3-7 cycloalkyl-, cyano, indanyl, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, Q1-, Q1-C(O)-, Q1-O-, Q1-S-, Q1-C1-4 alkyl-O-, or C1-4alkyl-C(O)-N(R3)-; Q1 is a 5-12 membered monocyclic aromatic ring optionally containing up to 4 heteroatoms selected from N and S, and is optionally substituted with halo, C1\_4 alkyl, C1\_4 alkylsulfonyl and  $C_{1-4}$  alkylC(=0)-;

A is 5-6 membered monocyclic aromatic ring optionally substituted with halo, C1-4 alkyl or C<sub>1-4</sub> alkoxy;

B is  $C_{3-7}$  cycloalkylene or  $C_{1-6}$  alkylene optionally substituted with an oxo group or  $C_{1-3}$ alkyl;

W is NH, N-C<sub>1-4</sub> alkyl, O or N-OH;

R<sup>2</sup> is H or C<sub>1-4</sub> alkyl;

Z is 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo,  $C_{1-4}$  alkyl, halo-substituted  $C_{1-4}$  alkyl,  $C_{1-4}$  $\underline{C_{2-4}}$  alkenyl,  $C_{1-4}$  alkoxy, nitro, amino, cyano,  $R^3C(=O)N(R^4)$ -,  $C_{1-4}$  alkyl-O(O=)C-,  $Q^2$ - $S(O)m^{-}, Q^{2}-O^{-}, Q^{2}-N(R^{3})$ - or  $Q^{2}$ -:

7346222928

L is halo,  $C_{1-4}$  alkyl, halo-substituted  $C_{1-4}$  alkyl, hydroxy,  $C_{1-4}$  alkoxy, halo-substituted  $C_{1-4}$ 4 alkoxy, mono- or di-(C1-4 alkyl)amino, cyano, HO-C1-4 alkyl, C1-4 alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkylC(=O)-, HO(O=)C-, C<sub>1-4</sub> alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino,  $C_{3-7}$  cycloalkyl,  $R^3C(=O)N(R^4)$ -,  $R^3N(R^4)C(=O)$ -,  $R^3N(R^4)S(O)m$ -,  $Q^2$ -,  $Q^2$ -C(=O)-,  $Q^2$ -

O-, Q2-C1-4alkyl-O-, or two adjacent L groups are optionally joined together to form an alkylene chain having 3 or 4 members in which one or two (non-adjacent) carbon atoms are optionally replaced by oxygen atoms;

m is 0 or 2;

R<sup>3</sup> and R<sup>4</sup> are independently selected from H and C<sub>1-4</sub> alkyl; and

O<sup>2</sup> is a 5 or 6 membered monocyclic aromatic ring, or a 8-12 membered tricyclic ring containing up to 3 heteroatoms selected from N and S, wherein said 5 or 6 membered monocyclic aromatic ring is optionally substituted with halo.

4. (currently amended) A compound according to Claim 3, wherein one of Y1, Y2, Y3 and Y4 is N and the others are independently selected from N, CH and C(L);R1 is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or C3-7 cycloalkyl, wherein said C1-8 alkyl is optionally substituted with halo, C1-3 alkyl, hydroxy, oxo, C1-4 alkoxy-, C1-4 alkyl-S(O)m-, C<sub>3-7</sub> cycloalkyl-, cyano, indanyl, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, Q<sup>1</sup>-,  $Q^{1}-C(=O)$ -,  $Q^{1}-O$ -,  $Q^{1}-S$ -,  $Q^{1}-C_{1-4}$  alkyl-O-, or  $C_{1-4}$ alkyl-C(O)-N( $R^{3}$ )-; Q1 is a 5 or 6 membered monocyclic aromatic ring optionally containing up to 4 heteroatoms

selected from N and S;

-8-

A is 5-6 membered monocyclic aromatic ring system optionally substituted with halo or C<sub>1-4</sub> alkyl;

B is  $\Theta$  C<sub>3-7</sub> cycloalkylene or C<sub>1-6</sub> alkylene optionally substituted with an oxo group or C<sub>1-3</sub> alkyl;

W is NH, N-C<sub>1-4</sub> alkyl, O or N-OH;

R<sup>2</sup> is H or C<sub>1-4</sub> alkyl;

Z is 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo,  $C_{1-4}$  alkyl, halo-substituted  $C_{1-4}$  alkyl,  $G_{1-4}$  $\underline{C_{2-4}}$  alkenyl,  $C_{1-4}$  alkoxy, nitro, amino, cyano,  $R^3C(=O)N(R^4)$ -,  $C_{1-4}$  alkyl-O(O=)C-,  $Q^2$ - $S(O)m^{2}$ ,  $O^{2}$ - $O^{2}$ - $N(R^{3})$ - or  $Q^{2}$ -; L is halo,  $C_{1-4}$  alkyl, halo-substituted  $C_{1-4}$  alkyl, hydroxy,  $C_{1-4}$  alkoxy, halo-substituted  $C_{1-4}$ 

4 alkoxy, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkylC(=0),  $\label{eq:ho} \mbox{HO(O=)C-, $C_{1-4}$ alkyl-O(O=)C-, $C_{1-4}$ alkylsulfonylamino, $C_{3-7}$ cycloalkyl, $R^3C(=O)NR^4$-, $R^3C(O)NR^4$-, $R^3C$  $R^3N(R^4)C(=0)$ -,  $R^3N(R^4)S(0)m$ -,  $Q^2$ -,  $Q^2$ -C(=0)-,  $Q^2$ -O-,  $Q^2$ -C<sub>1-4</sub>alkyl-O-, or two adjacent L groups are optionally joined together to form an alkylene chain having 3 or 4 members in which one or two (non-adjacent) carbon atoms are optionally replaced by oxygen atoms;

m is 0 or 2;

R<sup>3</sup> and R<sup>4</sup> are independently selected from H and C<sub>1-4</sub> alkyl; and

O<sup>2</sup> is 5 or 6 membered monocyclic aromatic ring or a 8-12 membered tricyclic ring optionally containing I sulfur atom wherein said 5 or 6 membered monocyclic aromatic ring is optionally substituted with halo.

5. (currently amended) A compound according to Claim 4, wherein one of Y1, Y2, Y3 and Y4 is N and the others are independently selected from N, CH and C(L);

PC9985A

F-385

 $R^1$  is  $C_{1-5}$  alkyl or  $C_{3-7}$  cycloalkyl, wherein said  $C_{1-5}$  alkyl is optionally substituted with  $C_{1-3}$  alkyl, hydroxy, oxo, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl,  $Q^1$ , or  $C_{1-4}$  alkyl-C(O)-N(H)-;

 $Q^1$  is 5-12 membered monocyclic aromatic ring system optionally containing up to 2 heteroatoms selected from N and S,

A is 5-6 membered monocyclic aromatic ring system;

B is  $C_{1-3}$  alkylene optionally substituted with  $C_{1-3}$  alkyl;

W is NH, N-C<sub>1-2</sub> alkyl or O;

 $\mathbb{R}^2$  is H;

Z is 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from N and S, wherein said 5-12 membered monocyclic aromatic ring is optionally substituted with halo,  $C_{1-4}$  alkyl, nitro,  $R^3C(=0)N(R^4)$ - or  $Q^2$ -;

L is halo,  $C_{1-4}$  alkyl, halo-substituted  $C_{1-4}$  alkyl, hydroxy,  $C_{1-4}$  alkoxy, halo-substituted  $C_{1-4}$  alkoxy, cyano, HO- $C_{1-4}$  alkyl, acetyl,  $R^3N(R^4)C(=0)$ -,  $R^3N(R^4)S(0)$ m-,  $Q^2$ -,  $Q^2$ -C(=0)-, or two adjacent L groups are joined together to form a methylenedioxy group;  $R^3$  and  $R^4$  are independently selected from H and  $C_{1-4}$  alkyl; and

Q2 is 5 or 6 membered monocyclic aromatic ring system.

6. (currently amended) A compound according to Claim 5, wherein one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> is N and the others are independently selected from N, CH and C-L;

 $R^1$  is  $C_{I-5}$  alkyl optionally substituted with  $C_{1-3}$  alkyl, hydroxy, oxo, 5 or 6 membered monocyclic aromatic ring, wherein said 5 or 6 membered monocyclic aromatic ring is containing I or 2 heteroatoms selected from N and S, or  $C_{1-4}$ alkyl-C(O)-N(R<sup>3</sup>)-;

A is phenyl;

B is  $C_{1-2}$  alkylene optionally substituted with methyl;

W is NH, N-CH<sub>3</sub> or O;

R<sup>2</sup> is H;

Z is 5-10 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from N and S, wherein said 5-10 membered monocyclic aromatic ring is optionally substituted with chloro, bromo, methyl, nitro, CH<sub>3</sub>C(=O)NH-, tBuC(=O)NH- or phenyl; and

L is chloro, methyl, trifuluoromethyl, hydroxy, methoxy, cyano, acetyl, -C(=O)NH<sub>2</sub>, trifuluoromethyloxy, methanesulfonyl, or 1-hydroxy-1-methyl-ethyl, or two adjacent L groups are joined together to form a methylenedioxy group.

7. (currently amended) A compound according to Claim 6, wherein

one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> is N and the others are independently selected from N, CH and

C-L C-(L);

R<sup>1</sup> is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, neopentyl, thiazolylethyl methylamino, dimethylamino, pyrrolidinyl, pyridyl, or 1-acetylamino-1-methylethyl;

A is phenyl;

B is ethylene or propylene;

W is NH, N-CH3 or O;

 $\mathbb{R}^2$  is H;

Z is phenyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, naphthyl or benzothienyl, said phenyl, pyrazolyl, thiazolyl, thiadiazolyl and thienyl being optionally substituted with one to three substituents independently selected from chloro, bromo, methyl, acetylamino, pivaloylamino, nitro and phenyl; and

L is chloro, methyl, trifuluoromethyl, hydroxy, methoxy, cyano, acetyl, -C(=O)NH<sub>2</sub>, trifuluoromethyloxy, methanesulfonyl, or 1-hydroxy-1-methyl-ethyl, or two adjacent L groups are joined together to form a methylenedioxy group.

- 8. (currently amended) A compound according to Claim 7, wherein
- $Y^1$ ,  $Y^2$ ,  $Y^3$  and  $Y^4$  are selected from the group consisting of
- a) Y<sup>1</sup> and Y<sup>3</sup> are C(L), Y<sup>2</sup> is CH and Y<sup>4</sup> is N;
- b) Y1 is CH, Y2 and Y3 are C(L) and Y4 is N;
- c) Y1, Y2 and Y3 are C(L) and Y4 is N;

- 11 -

PATENT PFIZER ANN ARBOR MI

PC9985A

T-403 P 015/026

F-385

- d)  $Y^1$  and  $Y^3$  are C(L),  $Y^2$  is N and  $Y^4$  is CH;
- e) Y1 is C(L) and Y2, Y3 and Y4 are CH;
- f. Y1, Y3 and Y4 are CH, and Y2 is C(L);
- g) Y1, Y2 and Y3 are CH, and Y4 is C(L);
- h) Y1 and Y2 are C(L), and Y3 and Y4 are CH;
- i) Y1 and Y3 are C(L), and Y2 and Y4 are CH;
- i) Y1 and Y4 are CH, and Y2 and Y3 are C(L);
- k) Y<sup>1</sup> and Y<sup>2</sup> are CH, Y<sup>3</sup> is C(L) and Y<sup>4</sup> is N;
- 1)  $Y^1$  and  $Y^3$  are CH,  $Y^2$  is C(L) and  $Y^4$  is N;
- m) Y1, Y2, Y3 and Y4 are CH;
- n)  $Y^1$  and  $Y^2$  are C(L),  $Y^3$  is CH and  $Y^4$  is N;
- e) Y1, Y2 and Y4 are CH, and Y3 is C(L);
- p)  $Y^1$  and  $Y^2$  are C(L),  $Y^3$  is N and  $Y^4$  is CH;
- a) Y1-and Y3 are C(L), and Y2 and Y4-are N;
- r) Y1 is C(L), Y2 and Y3 are CH, and Y4 is N; and
- s)  $Y^2$  is C(L),  $Y^1$  and  $Y^3$  are CH, and  $Y^4$  is N;

R1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, neopentyl, thiazolylethyl methylamino, dimethylamino, pyrrolidinyl, pyridyl, or 1-acetylamino-1-methylethyl;

A is phenyl;

B is ethylene or propylene;

W is NH, N-CH3 or O;

 $\mathbb{R}^2$  is H:

Z is phenyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, naphthyl or benzothienyl, said phenyl, pyrazolyl, thiazolyl, thiadiazolyl and thienyl being optionally substituted with one to three substituents independently selected from chloro, bromo, methyl, acetylamino, pivaloylamino, nitro and phenyl; and

L is chloro, methyl, trifuluoromethyl, hydroxy, methoxy, cyano, acetyl,  $-C(=O)NH_2$ , trifuluoromethyloxy, methanesulfonyl, or 1-hydroxy-1-methyl-ethyl, or two adjacent L groups are joined together to form a methylenedioxy group.

- 9. (currently amended) A compound according to Claim 8, wherein
- Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> are selected from the group consisting of
- a) Y<sup>1</sup> and Y<sup>3</sup> are C(L), Y<sup>2</sup> is CH and Y<sup>4</sup> is N;
- b)  $Y^1$  is CH.  $Y^2$  and  $Y^3$  are C(L) and  $Y^4$  is N;
- c) Y1, Y2 and Y3 are C(L) and Y4 is N; and
- d) Y1 and Y3 are C(L), Y2 is N and Y4 is CH;
- e) Y1-is C(L) and Y2, Y3 and Y4-are CH;
- f) Y1, Y3 and Y4 are CH, and Y2 is C(L);
- g) Y1, Y2 and Y3 are CH, and Y4 is C(L);
- h) Y1 and Y2 are C(L), and Y3 and Y4 are CH;
- i) Y1 and Y3 are C(L), and Y2 and Y4 are CH; and
- i) Y1 and Y4 are CH, and Y2 and Y3 are C(L);

R<sup>1</sup> is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, neopentyl, thiazolylethyl methylamino, dimethylamino, pyrrolidinyl, pyridyl, or 1-acetylamino-1-methylethyl;

A is phenyl;

B is ethylene or propylene;

W is NH, N-CH3 or O;

 $\mathbb{R}^2$  is H:

Z is phenyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, naphthyl or benzothienyl, said phenyl, pyrazolyl, thiazolyl, thiadiazolyl and thienyl being optionally substituted with one to three substituents independently selected from chloro, bromo, methyl, acetylamino, pivaloylamino, nitro and phenyl; and

L is chloro, methyl, trifuluoromethyl, hydroxy, methoxy, cyano, acetyl, -C(=O)NH2, trifuluoromethyloxy, methanesulfonyl, or 1-hydroxy-1-methyl-ethyl, or two adjacent L groups are joined together to form a methylenedioxy group.

10. (currently amended) A compound according to Claim 1 selected from  $3-(4-\{2-[(\{[(5-chloro-1,3-dimethyl-1h-pyrazol-4-yl)sulfonyl]amino\}carbonyl)amino]ethyl\}$ phenyl)-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine;

```
3-(4-\{2-[(\{[(2,4-\mathrm{dimethyl-1,3-thiazol-5-yl})\mathrm{sulfonyl}]\mathrm{amino}\}\mathrm{carbonyl})\mathrm{amino}]\mathrm{ethyl})\mathrm{-}2-\mathrm{ethyl-5,7-dimethyl-}3H\mathrm{-}\mathrm{imidazo}[4,5-b]\mathrm{pyridine};
```

 $N-[5-({[({2-[4-(2-ethyl-5,7-dimethyl-3}H-imidazo[4,5-b]pyridin-3-}$ 

yl)phenyl]ethyl}amino)carbonyl]amino}sulfonyl)-1,3,4-thiadiazol-2-yl]acetamide;

6-ethyl-5-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}earbonyl)amino|ethyl}phenyl)-5H[1,3|dioxolo[4,5-f]benzimida2ole;

6-chlore-5-cyane-2-cthyl-1-(4-{2-[({[(4-methylphenylsulfonyl]amine}carbonyl)amine}ethyl}phenyl)-1H-benzimidazole;

2-ethyl-5,7-dimethyl-3-(4-{2-[methyl({[(4-methylphenyl)sulfonyl]amino} carbonyl)amino]ethyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

2-ethyl-5,7-dimethyl-3-(4-{2-[({[(4-

methylphenyl)sulfonyl]amino}carbonyl)amino]propyl}phenyl)-3H-imidazo[4,5-b]pyridine;

2-[4-(2-ethyl-5,7-dimethyl-3*H*-imida2o[4,5-*b*]pyridin-3-yl)phenyl]-1-methylethyl (4-methylphenyl)sulfonylcarbamate;

5,7-dimethyl-3-(4- $\{2$ - $\{(\{(4$ -methylphenyl)sulfonyl]amino\}carbonyl)amino]ethyl $\}$ phenyl)-2-propyl-3H-imidazo[4,5-b]pyridine;

2-isopropyl-5,7-dimethyl-3-(4-{2-[({[(4-

methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-b]pyridine;

2-butyl-5,7-dimethyl-3-(4-{2-{({[(4-

methylphenyl) sulfonyl] amino] carbonyl) amino] ethyl) phenyl) -3 \$H\$-imidazo[4,5-\$b] pyridine;

2-isobutyl-5,7-dimethyl-3-(4-{2-[({[(4-

 $methyl phenyl) sulfonyl] amino \} carbonyl) amino ] ethyl \} phenyl) - 3 H-imidazo [4,5-b] pyridine;$ 

5,7-dimethyl-3-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-2-neopentyl-3*H*-imidazo[4,5-*b*]pyridine;

5,7-dimethyl-3-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-2-[2-(1,3-thiazol-2-yl)ethyl]-3*H*-imidazo[4,5-*b*]pyridine;

3-{4-[2-({[(4-biphenylsulfonyl)amino]carbonyl}amino)ethyl]phenyl}-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

2-ethyl-5,7-dimethyl-3-{4-[2-({[(1-naphthylsulfonyl)amino]carbonyl}amino)ethyl]phenyl}-3H-imidazo[4,5-b]pyridine;

```
2-ethyl-5, 7-dimethyl-3-\{4-[2-(\{[(2-naphthylsulfonyl)amino] carbonyl\}amino)ethyl]phenyl\}-1-(\{[(2-naphthylsulfonyl)amino] carbonyl\}amino)ethyl]phenyl\}-1-(\{[(2-naphthylsulfonyl)amino] carbonyl\}amino)ethyl]phenyl\}-1-(\{[(2-naphthylsulfonyl)amino] carbonyl\}amino)ethyl]phenyl\}-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]phenyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]phenyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]phenyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino)ethyl]-1-(\{[(2-naphthylsulfonyl)amino] carbonyl]amino] carbonyl]amino[[(2-naphthylsulfonyl)amino] carbonyl]amino[[(2-naphthylsulfonyl)amino] carbonyl]amino[[(2-naphthylsulfonyl)amino] carbonyl]amino[[(2-naphthylsulfonyl)amino] carbonyl]amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino] carbonyl]amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsulfonyl)amino[[(2-naphthylsul
     3H-imidazo[4,5-b]pyridine;
```

- 14 -

PATENT PFIZER ANN ARBOR MI

2-ethyl-5,7-dimethyl-3-(4-{2-[({[(2-thienyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-b]pyridine;

 $3-(4-\{2-[(\{[(5-chloro-2-thienyl)sulfonyl]amino\} carbonyl)amino]ethyl\}phenyl)-2-ethyl-5,7-amino]ethyl$ dimethyl-3H-imidazo[4,5-b]pyridine;

 $3-(4-\{2-[(\{[(4,5-dichloro-2-thienyl)sulfonyl]amino\} carbonyl)amino]ethyl\} phenyl)-2-ethyl-2-[(\{[(4,5-dichloro-2-thienyl)sulfonyl]amino\} carbonyl)amino]ethyl]$ 5,7-dimethyl-3H-imidazo[4,5-b]pyridine;

 $3-\{4-[2-(\{[(1-benzothien-2-ylsulfonyl)amino]carbonyl\}amino)ethyl]phenyl\}-2-ethyl-5, 7-independent amino am$ dimethyl-3H-imidazo[4,5-b]pyridine;

 $3-(4-\{2-[(\{[(2-chlorophenyl)sulfonyl]amino\}carbonyl)amino]ethyl\}phenyl)-2-ethyl-5,7-amino]ethyl]$ dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

2-ethyl-5,6-dimethyl-3-(4-{2-[({[(4-

methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-b]pyridine; 5,6-dichloro-2-ethyl-3-(4-{2-[({[(4-

methylphenyl) sulfonyl] amino] carbonyl) amino] ethyl) phenyl) - 3 H-imidazo [4,5-b] pyridine; amino] ethylphenyl) - 3 H-imidazo [4,5-b] pyridine; amino] ethylphenyl - 3 H-imidazo [4,5-b] ethylp5-chloro-2-ethyl-7-methyl-3-(4-{2-[({[(4-

methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-b]pyridine; 6-cyano-2-ethyl-5,7-dimethyl-3-(4-{2-[({[(4-

 $methylphenyl) sulfonyl] amino \} carbonyl) amino ] ethyl) phenyl) - 3H-imidazo [4,5-b] pyridine;$ 2-ethyl-4,6-dimethyl-1-(4-{2-[({[(4-

 $methyl phenyl) sulfonyl] amino] carbonyl) amino] ethyl) phenyl) -1 \\ H-imidazo [4,5-c] pyridine;$ 

4-methyl-2-ethyl-3 (4-{2-{({{(4-

methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)benzimidazole; 7-chloro-2-cthyl-3-(4-{2-[({[(4-

methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)benzimidazole; 5-methoxy-2-ethyl-3-(4-{2-[({[(4-

methylphenyl)sulfonyl|amino|carbonyl)amino|ethyl}phenyl)benzimidazole; 5-acetyl-2-ethyl-3-(4-{2-{({{(-4-)}}

methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)benzimidazole;

```
5 cyano 2 cthyl 1 (4 {2-[({[(4-
\underline{methylphenyl)sulfonyl[amino]carbonyl]amino]ethyl]phenyl)-\underline{L}W-benzimidazole;}
2-ethyl-5-hydroxy-1-(4-{2-[({{-
{\color{blue} \mathbf{methylphenyl)} \mathbf{sulfonyl} \mathbf{amino} \mathbf{carbonyl)} \mathbf{amino} \mathbf{lethyl} \mathbf{phenyl)} \mathbf{-1} \mathbf{H-benzimidazole}; \\
2-ethyl-4,5-dimethyl-1-(4-{2-[({[(4-
methylphenyl)sulfonyl]amino}carbonyl)amino]cthyl]phenyl)-1II-benzimidazole;
4,6 dimethyl-2 ethyl-3-(4-{2-{({{4-{1.5}}}}}
methylphonyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)benzimidazole;
5,6-dimethyl 1 (4-{2-[({[(4-methylphenyl)sulfonyl]amino}earbonyl)amino]ethyl}phenyl)
1.H-benzimidazole;
5,6-dichloro-2-ethyl-1-(4-{2-|({{(4-
\frac{methylphenyl)sulfonyl[amino]carbonyl)amino]cthyl]phenyl)-1 \emph{M-benzimidazole};}{methylphenyl)-1 \emph{M-benzimidazole};}
2-[4-(5,6-diehloro-2-ethyl-1/I-benzimidazol-1-yl)phenyl]ethyl-(4-
methylphenyl)sulfonylearbamate;
6-chloro 5-trifluoromethyl 1 (4-{2-}(([(4-
 methylphenyl)sulfonyl\{amino\}carbonyl\{amino\}ethyl\{phenyl\}-\{amino\}enzimidazole\{amino\}
 4-(6-chlore-2-cthyl-5 trifluoromethyl-1H benzimidazol-1-yl)phenethyl-(4-
 methylphenyl)sulfonylearbamate;
 \underline{methylphenyl)sulfonyl]amino\}carbonyl)amino]ethyl\}phenyl)-1 \textit{H-benzimidazole};
 6-chloro-2-ethyl-1-(4-{2-{({{({({(4-)})}}}
 \underline{mothylphenyl)} sulfonyl] a mino \} carbonyl) a mino ] ethylphenyl) -1 \underline{H-benzimidazole-5-}
 <del>carboxamide;</del>
 2-ethyl-3-{4-[2-({[({3-
 [hydroxy(oxido)amino]phenyl}sulfonyl)amino]carbonyl}amino)ethyl]phenyl}-5,7-dimethyl-
 3H-imidazo[4,5-b]pyridine;
 dimethyl-3H-imidazo[4,5-b]pyridine;
 yl)phenyl]ethyl}amino)carbonyl]amino}sulfonyl)phenyl]-2,2-dimethylpropanamide;
```

- dimethyl-3H-imidazo[4,5-b]pyridine; dimethyl-3H-imidazo[4,5-b]pyridine;  $3-(4-\{2-[(\{[(5-chloro-2-thienyl)sulfonyl]amino\} carbonyl)amino] ethyl\} phenyl)-2-ethyl-5, 7-like amino ami$ dimethyl-3H-imidazo[4,5-b]pyridine;  $3-(4-\{2-[(\{[(5-bromo-2-thienyl)sulfonyl]amino\} carbonyl)amino] ethyl\} phenyl)-2-ethyl-5, 7-bromo-2-thienyl) amino phenyl) amino phenyl amino pheny$ dimethyl-3H-imidazo[4,5-b]pyridine; 3-(4-{2-[({[(2-bromophenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-2-ethyl-5,7dimethyl-3H-imidazo[4,5-b]pyridine; 3-{4-[2-({[({4-chloro-3-nitrophenyl}sulfonyl)amino]carbonyl}amino)ethyl]phenyl}-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine; 2-[4-(2-ethyl-4,6-dimethyl-1\$H\$-imidazo[4,5-c] pyridin-1-yl) phenyl] ethyl (4-c) + (2-ethyl-4,6-dimethyl-1\$H\$-imidazo[4,5-c] pyridin-1-yl] phenyl ethyl ethmethylphenyl)sulfonylcarbamate; 2-{4-[5,7-dimethyl-2-(methylamino)-3H-imidazo[4,5-b]pyridin-3-yl]phenyl}ethyl (4methylphenyl)sulfonylcarbamate;
- $N-\{[(2-\{4-[5,7-\mathrm{dimethyl-}2-(\mathrm{methylamino})-3H-\mathrm{imida2o}[4,5-b]) \text{pyridin-}3-b\}\}$

yl]phenyl}ethyl)amino]carbonyl}-4-methylbenzenesulfonamide;

N-{[(2-{4-[2-ethyl-5-(1-hydroxy 1-methylethyl) 1H-benzimidazol-1yl]phenyl]ethyl)amino]carbenyl] 4-methylbenzenesulfonamide;

2-ethyl-4,6-dimethyl-1 (4-{2-{({[(4-

methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl]phenyl) 111 benzimidazole-5earboxamide;

- 2-{4-[6-chloro-2-cthyl-5 (trifluoromethyl) 1H benzimidazol-1-yl]phenyl}ethyl (2chlorophenyl)sulfonylearbamate;
- 2-{5-{6-chloro-2-ethyl-5-(trifluoromethyl)-1H-benzimidazol-1-yl]-2-pyridinyl}ethyl (4methylphenyl)sulfonylcarbamate;
- 2-{4-[6-chloro-2-ethyl-5-(trifluoromethyl)-1H-benzimidazol-1-yl]phonyl}ethyl (5-methyl-2-pyridinyl)sulfonylearbamate;
- 2-{4-{6-chlore-2-(111-pyrazel-3-yl) 5 (trifluoremethyl) 111-benzimidazel-1yl]phenyl]ethyl (4-methylphenyl)sulfonylearbamate;

- 2-{4-[6-chlore-2-(4-pyridinyl)-5-(trifluoremethyl)-1H-benzimidazel-1-yl}phenyl}ethyl-(4methylphonyl)sulfonylearbamate;
- 2-{4-{5-(aminocarbonyl) 6-chloro-2-ethyl-1H-benzimidazol-1-yl]phenyl}ethyl (4methylphenyl)sulfonylearbamate;

N-{[(2-{4-[6-chlore-2-ethyl-5-(methylsulfenyl)-111-benzimidazel-1yllphenyllethyllamino|carbonyll-4-methylbenzenesulfonamide;

2-[4-[6-chloro-2-ethyl-5-(methylsulfonyl)-1H-benzimidazol-1-yl]phenyl}ethyl-(4methylphenyl)sulfonylcarbamates

 $N-[({2-[4-(2-ethyl-5,7-dimethyl-3}H-imidazo[4,5-b]pyridin-3-$ 

yl)phenyl]ethyl}amino)carbonyl]-2-thiophenesulfonamide;

2-[4-(4,6-dimethyl-2-phenyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl (4methylphenyl)sulfonylcarbamate;

2-[4-(2-butyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl (4methylphenyl)sulfonylcarbamate;

- 2-{4-{6-chloro-2-ethyl-5-(trifluoromethyl)-1H-benzimidazol-1-yl]phenyl}ethyl (5-chloro-1.3 dimethyl-1H-pyrazol-4-yl)sulfonylearbamate;
- $2-\{4-[4,6-dimethyl-2-(3-phenylpropyl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl\}ethyl$  (4methylphenyl)sulfonylcarbamate;
- 2-[4-[6-chlore-2-(2-pyridinyl)-5-(trifluoremethyl)-1H-benzimidazel-1-yl]phenyl]ethyl (4methylphenyl)sulfonylcarbamato;
- (1S) 2-{4-[6-ehloro-2-ethyl-5 (trifluoromethyl)-1H-benzimidazol-1-yl]phenyl]-1methylethyl (4-methylphenyl)sulfonylearbamate;
- 2-[6-[6-chloro-2-ethyl-5 (trifluoromethyl) 111 benzimidazol 1 yl] 3-pyridinyl]ethyl (4methylphenyl)sulfonylcarbamate;

N-{[(2-{4-[6-chloro-2 (1-hydroxy-1-methylethyl)-5-(trifluoromethyl)-1H-benzimidazol-1yllphenyllethyl)aminolearbonyll-4-methylbenzenesulfonamide;

yl]phenyl}ethyl)amino]carbonyl}-4-methylbenzenesulfonamide;

 $2-\{4-[2-(1,1-dimethylethyl)-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl]phenyl\}$  ethyl (4methylphenyl)sulfonylcarbamate;

2-{4-{2-{1-(acetylamine) 1 methylethyl} 6-chlore-5 (trifluoromethyl) 1}} benzimidazol-1-yl]phenyl]ethyl (4-methylphenyl)sulfonylcarbamate;
6-chlore-2-cthyl-1-(4-{2-{methyl({{(4-methylphenyl)sulfonyl]amine}carbonyl)amine}cthyl}phenyl)-1}} benzimidazole-5-carboxamide; and salts thereof.

11. (currently amended) A compound according to Claim 1 selected from  $\textcolor{red}{6-ethyl-5-(4-\{2-[(\{[(4-methylphenyl)sulfonyl]amino\}earbonyl)amino]ethyl]phenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl)sulfonyl]amino\}earbonyl)amino]ethyl]phenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl)sulfonyl]amino\}earbonyl)amino]ethylphenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl)sulfonyl]amino\}earbonyl)amino]ethylphenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl)sulfonyl]amino\}earbonyl)amino]ethylphenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl)sulfonyl]amino\}earbonyl)amino]ethylphenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl]amino\}earbonyl)amino]ethylphenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl]amino]earbonyl)amino]ethylphenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl]amino]earbonyl)amino]ethylphenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl]amino]earbonyl)amino]ethylphenyl)} \textcolor{red}{5H-benyl-5-(4-\{2-[(\{[(4-methylphenyl]amino]earbonyl)amino]earbonyl)} \textcolor{red}{5H-benyl-5-(4-[(\{[(4-methylphenyl]amino]earbonyl)am$ [1,3]dioxolo[4,5-f]benzimidazole; 6-chlore-5-cyane-2-cthyl-1-(4-{2-[({{(4- $\underline{mothylphenylsulfonyl]amino} \\ \underline{carbonyl)amino} \\ \underline{ethyl} \underline{phenyl)} \underline{-1} \\ \underline{H-benzimidazole};$ 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl]-1-methylethyl (4methylphenyl)sulfonylcarbamate; 5,7-dimethyl-3-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-2-[2-(1,3-thiazol-2-yl)ethyl]-3H-imidazo[4,5-b]pyridine; 2-ethyl-5,7-dimethyl-3-(4-{2-[({[(2-thienyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-b]pyridine; 3-(4-{2-[({[(2-chlorophenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-2-ethyl-5,7dimethyl-3H-imidazo[4,5-b]pyridine; 2-ethyl-5,6-dimethyl-3-(4-{2-[({[(4methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-b]pyridine; 5,6-dichloro-2-ethyl-3-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl} phenyl)-3H-imidazo[4,5-b]pyridine; 2-ethyl-4,6-dimethyl-1-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino] ethyl}phenyl)-1H-imidazo[4,5-c]pyridine; 5 methoxy-2-ethyl-3-(4-{2-{({{((4-methylphenyl)sulfonyl}amino}carbonyl)amino} ethyl]phenyl)benzimidazole; 5-acetyl-2-ethyl-3-(4-{2-{(({(4-methylphenyl)sulfonyl]amino}carbonyl)amino} ethyl]phenyl)benzimidazole; 5-cyano-2-cthyl-1-(4-{2-{({{(4-methylphenyl)sulfonyl]amino}carbonyl)amino} ethyl)phenyl) 1H-benzimidazele;

F-385

```
2-ethyl 5-hydroxy 1-(4-{2-[(-{(--methylphonyl)sulfonyl}amino)earbonyl)amino}
ethyl]phenyl)-1H-benzimidazole;
2-ethyl-4,5-dimethyl-1-(4-{2-{({[(4-methylphenyl)sulfonyl]amino}earbonyl)amino}
ethyl) phenyl) 1H benzimidazole;
4-(6-chlore-2-ethyl-5-trifluoromethyl-1H-benzimidazel-1-yl)phenethyl-(4-
methylphenyl)sulfonylcarbamate; and
6-chlore-2-ethyl-1-(4-{2-{({{(4-methylphenyl)sulfonyl}amine}carbonyl)amine}
ethyl]phenyl)-1H-benzimidazole-5-carboxamide;
2-[4-(2-\text{cthy}]-4,6-\text{dimethy}]-1H-\text{imidazo}[4,5-c]pyridin-1-yl)phenyl]ethyl (4-
methylphenyl)sulfonylcarbamate;
2-{4-[5,7-dimethyl-2-(methylamino)-3H-imidazo[4,5-b]pyridin-3-yl]phenyl}ethyl (4-
methylphenyl)sulfonylcarbamate;
N-\{[(2-\{4-[5,7-\mathrm{dimethyl-}2-(\mathrm{methylamino})-3H-\mathrm{imidazo}[4,5-b]]\text{pyridin-}3-b]\}
yl]phenyl}ethyl)amino]carbonyl}-4-methylbenzenesulfonamide;
N {[(2-{4-[2-ethyl-5-(1-hydroxy-1-methylethyl)-1H-benzimidazol-1-
yllphenyllethyl)aminolearbonyll-4-methylbenzenesulfonamide;
2-ethyl-4,6-dimethyl-1 (4-{2-{({{(4-
methylphenyl)sulfonyl]amino]carbonyl)amino]ethyl}phenyl)-1H-benzimidazole-5-
earboxamide:
2-{4-{6-chloro-2-ethyl-5-(trifluoromethyl)-111-benzimidazol-1-yl}phenyl}ethyl (2-
ehlorophenyl)sulfonylearbamate;
2-[5-[6-chloro-2-ethyl-5-(trifluoromethyl) 1H benzimidazol-1-yl]-2-pyridinyl}ethyl-(4-
methylphenyl)sulfonylcarbamate;
2-{4-[6-chlore-2-cthyl-5-(trifluoromethyl)-111-benzimidazol-1-yl]phenyl}ethyl-(5-methyl-
2-pyridinyl)sulfonylearbamate;
2-[4-[6-chloro-2-(1H-pyrazol-3-yl)-5 (trifluoromethyl)-1H-benzimidazol-1-
yl]phenyl]ethyl (4-methylphenyl)sulfonylcarbamate;
 2-[4-[6-chloro-2-(4-pyridinyl)-5-(trifluoromethyl)-1#-benzimidazol-1-yl]phenyl]ethyl (4-
```

2-14-15-(nminocarbonyl)-6-chloro-2-cthyl-1H-benzimidazol-1-yl|phenyl|cthyl (4-

methylphenyl)sulfonylearbamate;

methylphenyl)sulfonylcarbamate;

T-405 P.024/026 F-385 **PCAAA** 

```
N-{[(2-{4-[6-ehloro-2-ethyl-5-(methylsulfonyl)-1H-benzimidazol-1-
yl]phenyl]ethyl)amino]carbonyl}-4-methylbenzenesulfonamide;
2-{4-{6-chloro-2-ethyl-5-(methylsulfonyl) 1H-benzimidazol-1-yl]phenyl}ethyl (4-
methylphenyl)sulfonylearbamate;
```

- 20 -

 $\mathcal{N}$ -[({2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-

PATENT PFIZER ANN ARBOR MI

yl)phenyl]ethyl}amino)carbonyl]-2-thiophenesulfonamide;

 $2-[4-(4,6-\mathrm{dimethyl-2-phenyl-1}H-\mathrm{imidazo}[4,5-c]\mathrm{pyridin-1-yl})\mathrm{phenyl}]\mathrm{ethyl}\ (4-c)$ methylphenyl)sulfonylcarbamate;

2-[4-(2-butyl-4,6-dimethyl-1H-imidazo[4,5-c] pyridin-1-yl) phenyl] ethyl (4-c) pyridin-1-yl) phenyl (4-c) pyridin-1-yl) phenyl phenyl phenyl phenyl phenyl phenyl phenyl pyridin-1-yl) phenyl phenylmethylphenyl)sulfonylcarbamate;

2-{4-[6-chlore-2-ethyl-5-(trifluoromethyl)-1# benzimidazel-1-yl]phenyl}ethyl (5-chlore-1,3 dimethyl-1H-pyrazol 4-yl)sulfonylcarbamate;

 $2-\{4-[4,6-\mathrm{dimethyl}-2-(3-\mathrm{phenylpropyl})-1H-\mathrm{imidazo}[4,5-c]\mathrm{pyridin}-1-\mathrm{yl}]\mathrm{phenyl}\}\mathrm{ethyl}\ (4-1)$ methylphenyl)sulfonylcarbamate;

2-{4-[6-chloro-2-(2-pyridinyl)-5-(trifluoromethyl)-1#-benzimidazol-1-yl]phenyl]ethyl (4methylphenyl)sulfonylearbamate;

(1.5) 2 {4-[6-chlore-2-ethyl-5-(trifluoremethyl)-1H-benzimidazel-1-yl]phenyl} 1 methylethyl (4 methylphenyl)sulfonylearbamate;

2-{6-{6-chlore-2-cthyl-5-(trifluoromethyl) 1#-benzimidazol-1-yl}-3-pyridinyl}ethyl (4methylphenyl)sulfonylearbamato;

N-{[(2-{4-[6-ehloro-2-(1-hydroxy-1-methylothyl)-5-(trifluoromethyl)-1H-benzimidazol-1yl]phenyl]ethyl)amino]earbonyl} 4-methylbenzenesulfonamide; and

 $N-\{[(2-\{4-[5,7-dimethyl-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl]-3H-imidazo[4,5-b]pyridin-3-yl]-3H-imidazo[4,5-b]pyridin-3-yl]-3H-imidazo[4,5-b$ 

yl]phenyl}ethyl)amino]carbonyl}-4-methylbenzenesulfonamide;

methylphenyl)sulfonylcarbamate;

2-{4-[2-{1-(acetylamino)-1-methylethyl]-6-chlore-5-(trifluoromethyl)-1H-benzimidazol-1yllphenyllethyl (4-methylphenyl)sulfonylearbamate;

 $\textcolor{red}{6-chloro-2-cthyl-1-(4-\{2-\{methyl(\{\{(4-methylphenyl)sulfonyl\}amino\}earbonyl)amino\}}\\$ ethyl]phenyl) 111-benzimidazole-5-carboxamide; and salts thereof.

## 13. (canceled)

- 14. A pharmaceutical formulation comprising a compound of Claim 1, a pharmaceutically acceptable carrier and, optionally, one or more other pharmacologically active ingredients.
  - 15. (canceled)
  - 16. (canceled)
  - 17. (new) A compound of formula

    2-ethyl-4,6-dimethyl-1-(4-{2-[({[(4-methyl-1-(4-{2-[({[(4-methyl-1-midazo[4,5-C})pyridine.
  - 18. (new) A pharmaceutical composition for the treatment of a disorder or condition mediated by prostaglandin in mammal including a human, which comprises an effective amount of a compound of Claim 17, or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier.
  - 19. (new) A pharmaceutical formulation comprising a compound of Claim 17, a pharmaceutically acceptable carrier and optionally, one or more other pharmacologically active ingredients.